BioAffinity Technologies Operating Income Over Time
| BIAF Stock | USD 0.85 0.10 13.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out BioAffinity Technologies Performance and BioAffinity Technologies Correlation. BioAffinity | Build AI portfolio with BioAffinity Stock |
Can Biotechnology industry sustain growth momentum? Does BioAffinity have expansion opportunities? Factors like these will boost the valuation of BioAffinity Technologies. Projected growth potential of BioAffinity fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating BioAffinity Technologies demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (13.83) | Revenue Per Share | Quarterly Revenue Growth (0.39) | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies' value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because BioAffinity Technologies' market value can be influenced by many factors that don't directly affect BioAffinity Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioAffinity Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioAffinity Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioAffinity Technologies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare bioAffinity Technologies and related stocks such as Artelo Biosciences, GT Biopharma, and Mobile health Network Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARTL | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.2 K) | (29.7 K) | (232.8 K) | (2.3 M) | (3.2 M) | (4.7 M) | (7.4 M) | (10.3 M) | (9.9 M) | (10.1 M) | (9.1 M) | (8.6 M) |
| GTBP | (50 K) | (3.9 M) | (3.5 M) | (793 K) | (2.4 M) | (8.9 M) | (9.4 M) | (135.6 M) | (250.1 M) | (11.5 M) | (6.8 M) | (57.5 M) | (21.3 M) | (13.6 M) | (14.4 M) | (12.9 M) | (13.6 M) |
| MNDR | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | (474.9 K) | 196 K | (2.4 M) | (15.6 M) | (2.7 M) | (2.4 M) | (2.5 M) |
| WOK | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 7.7 M | 1.8 M | 486.5 K | (3.7 M) | (2.5 M) | (2.2 M) | (2.1 M) |
| CARM | (12.7 M) | (12.7 M) | (19.5 M) | (16.6 M) | (32.9 M) | (35.2 M) | 6.2 M | (20 M) | (25.7 M) | (36.9 M) | (28.4 M) | (28.2 M) | (56.2 M) | (88.7 M) | (62.2 M) | (56 M) | (53.2 M) |
| PBM | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (1.3 M) | (2.8 M) | (3.7 M) | (3.3 M) | (3.1 M) |
| REVB | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 10.3 M | 18.8 M | 32.7 M | 38.9 M | (3.6 K) | (145.5 K) | (12 M) | (10.9 M) | (8.7 M) | (8 M) | (7.2 M) | (6.8 M) |
| PTIX | (491 K) | (491 K) | (673 K) | (975 K) | (975 K) | (491 K) | (2.2 M) | (2.4 M) | (2.3 M) | (2.1 M) | (2.6 M) | (4.1 M) | (3.6 M) | (4.5 M) | (5.7 M) | (5.1 M) | (5.4 M) |
| LIPO | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (56.9 K) | (1.9 M) | (2.6 M) | (4.7 M) | (5.1 M) | (4.6 M) | (4.3 M) |
bioAffinity Technologies and related stocks such as Artelo Biosciences, GT Biopharma, and Mobile health Network Operating Income description
Operating Income is the amount of profit realized from bioAffinity Technologies operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of bioAffinity Technologies is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| bioAffinity Technologies | BIAF |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3300 Nacogdoches Road, |
| Exchange | NASDAQ Exchange |
USD 0.85
Check out BioAffinity Technologies Performance and BioAffinity Technologies Correlation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
BioAffinity Technologies technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.